Restructuring of the extracellular matrix in diabetic wounds and healing: A perspective

Pharmacological Research

Volumn 107, Issue , 2016, Pages 243-248

  Chang, Mayland ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Diabetic wounds; Extracellular matrix; MMP 8; MMP 9; ND 336

Indexed keywords

ACLERASTIDE; ANGIOTENSIN II; BECAPLERMIN; GELATINASE B; LAMININ; MATRIX METALLOPROTEINASE INHIBITOR; ND 322; ND 336; NEUTROPHIL COLLAGENASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL INFILTRATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL REGENERATION; CLINICAL TRIAL (TOPIC); DIABETIC FOOT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; ENDOTHELIUM CELL; EPITHELIZATION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMMUNOREACTIVITY; KERATINOCYTE; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WOUND HEALING; ANIMAL; DIABETES COMPLICATIONS; DRUG EFFECTS; METABOLISM;

ANIMALS; DIABETES COMPLICATIONS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; WOUND HEALING;

EID: 84962657730     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.03.008     Document Type: Article

References (79)

1. J.B. Rice, and et al. Burden of diabetic foot ulcers for medicare and private insurers Diabetes Care 37 3 2014 651 658
2. N. Singh, D.G. Armstrong, and B.A. Lipsky Preventing foot ulcers in patients with diabetes JAMA 293 2 2005 217 228
3. E.J. Peters, D.G. Armstrong, and L.A. Lavery Risk factors for recurrent diabetic foot ulcers: site matters Diabetes Care 30 8 2007 2077 2079
4. N. Ziyadeh, D. Fife, A.M. Walker, G.S. Wilkinson, and J.D. Seeger A matched cohort study of the risk of cancer in users of becaplermin Adv. Skin Wound Care 24 1 2011 31 39
5. Centers for Disease Control and Prevention (2014) National Diabetes Statistics Report: Estimates of diabetes and its burden in the United States. (Atlanta, GA).
6. L.V. Fortington, and et al. Short and long term mortality rates after a lower limb amputation Eur. J. Vasc. Endovasc. Surg. 46 1 2013 124 131
7. P. Jurasz, A.W. Chung, A. Radomski, and M.W. Radomski Nonremodeling properties of matrix metalloproteinases: the platelet connection Circ. Res. 90 10 2002 1041 1043
8. A.M. Manicone, and J.K. McGuire Matrix metalloproteinases as modulators of inflammation Semin. Cell Dev. Biol. 19 1 2008 34 41
9. A.C. Newby Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates Cardiovasc. Res. 69 3 2006 614 624
10. L. Nissinen, and V.M. Kahari Matrix metalloproteinases in inflammation Biochim. Biophys. Acta 1840 8 2014 2571 2580
11. W.C. Parks, C.L. Wilson, and Y.S. Lopez-Boado Matrix metalloproteinases as modulators of inflammation and innate immunity Nat. Rev. Immunol. 4 8 2004 617 629
12. M.G. Rohani, and W.C. Parks Matrix remodeling by MMPs during wound repair Matrix Biol. 44-46 2015 113 121
13. J.E. Rundhaug Matrix metalloproteinases and angiogenesis J. Cell Mol. Med. 9 2 2005 267 285
14. M. Fanjul-Fernandez, A.R. Folgueras, S. Cabrera, and C. Lopez-Otin Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models Biochim. Biophys. Acta 1803 1 2010 3 19
15. I.M. Clark, T.E. Swingler, C.L. Sampieri, and D.R. Edwards The regulation of matrix metalloproteinases and their inhibitors Int. J. Biochem. Cell Biol. 40 6-7 2008 1362 1378
16. C.H. Heldin, and B. Westermark Mechanism of action and in vivo role of platelet-derived growth factor Physiol. Rev. 79 4 1999 1283 1316
17. E.A. Bauer, T.W. Cooper, J.S. Huang, J. Altman, and T.F. Deuel Stimulation of in vitro human skin collagenase expression by platelet-derived growth factor Proc. Natl. Acad. Sci. U. S. A. 82 12 1985 4132 4136
18. D.G. Armstrong, and E.B. Jude The role of matrix metalloproteinases in wound healing J. Am. Podiatr. Med. Assoc. 92 1 2002 12 18
19. A. Gutierrez-Fernandez, and et al. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8) FASEB J. 21 10 2007 2580 2591
20. P.K. Mehta, and K.K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am. J. Physiol. Cell Physiol. 292 1 2007 C82 97
21. U.M. Steckelings, and et al. Human skin: source of and target organ for angiotensin II Exp. Dermatol. 13 3 2004 148 154
22. I.A. Arenas, Y. Xu, P. Lopez-Jaramillo, and S.T. Davidge Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha Am. J. Physiol. Cell Physiol. 286 4 2004 C779 784
23. R.W. Guo, L.X. Yang, H. Wang, B. Liu, and L. Wang Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells Regul. Pept. 147 1-3 2008 37 44
24. H. Colognato, and P.D. Yurchenco Form and function: the laminin family of heterotrimers Dev. Dyn. 218 2 2000 213 234
25. G. Giannelli, J. Falk-Marzillier, O. Schiraldi, W.G. Stetler-Stevenson, and V. Quaranta Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5 Science 277 5323 1997 225 228
26. N. Koshikawa, G. Giannelli, V. Cirulli, K. Miyazaki, and V. Quaranta Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5 J. Cell Biol. 148 3 2000 615 624
27. S. Schenk, and et al. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution J. Cell Biol. 161 1 2003 197 209
28. A. Yabluchanskiy, Y. Ma, R.P. Iyer, M.E. Hall, and M.L. Lindsey Matrix metalloproteinase-9: Many shades of function in cardiovascular disease Physiology (Bethesda) 28 6 2013 391 403
29. Y. Momota, and et al. Laminin alpha3 LG4 module induces keratinocyte migration: involvement of matrix metalloproteinase-9 J. Recept. Signal. Transduct. Res. 25 1 2005 1 17
30. M.A. Nugent, and R.V. Iozzo Fibroblast growth factor-2 Int. J. Biochem. Cell Biol. 32 2 2000 115 120
31. P. Bao, and et al. The role of vascular endothelial growth factor in wound healing J. Surg. Res. 153 2 2009 347 358
32. M. Makela, and et al. Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes Exp. Cell Res. 251 1 1999 67 78
33. L.J. McCawley, P. O'Brien, and L.G. Hudson Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)-mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9 J. Cell Physiol. 176 2 1998 255 265
34. B.K. Pilcher, and et al. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix J. Cell Biol. 137 6 1997 1445 1457
35. N. Hattori, and et al. MMP-13 plays a role in keratinocyte migration, angiogenesis, and contraction in mouse skin wound healing Am. J. Pathol. 175 2 2009 533 546
36. E. Olaso, and et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2 J. Biol. Chem. 277 5 2002 3606 3613
37. W. Risau, and et al. Platelet-derived growth factor is angiogenic in vivo Growth Factors 7 4 1992 261 266
38. N. Papanas, and E. Maltezos Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int. J. Low Extrem. Wounds 6 1 2007 37 53
39. A. Olivera, and S. Spiegel Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens Nature 365 6446 1993 557 560
40. D.L. Steed Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group J. Vasc. Surg. 21 1 1995 71 78 (discussion 79-81)
41. T.J. Wieman, J.M. Smiell, and Y. Su Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study Diabetes Care 21 5 1998 822 827
42. P.A. D'Hemecourt, J.M. Smiell, and M.R. Karim Effect of sodium carbomethylcellulose aqueous-based gel vs. becaplermin gel in patients with non-healing lower extremity diabetic ulcers Wounds 10 1998 69 75
43. J.M. Embil, and et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy Wound Repair Regen. 8 3 2000 162 168
44. D.J. Margolis, C. Bartus, O. Hoffstad, S. Malay, and J.A. Berlin Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers Wound Repair Regen. 13 6 2005 531 536
45. S. Vukelic, and K.K. Griendling Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift Circ. Res. 114 5 2014 754 757
46. E. Escobar, T.S. Rodriguez-Reyna, O. Arrieta, and J. Sotelo Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer Curr. Vasc. Pharmacol. 2 4 2004 385 399
47. U. Kintscher, and et al. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes Hypertension 37 Suppl. 2 2001 587 593
48. Y. Suzuki, and et al. Inflammation and angiotensin II Int. J. Biochem. Cell Biol. 35 6 2003 881 900
49. R. Tamarat, J.S. Silvestre, M. Durie, and B.I. Levy Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways Lab. Invest. 82 6 2002 747 756
50. M. Kurosaka, and et al. Reduced angiogenesis and delay in wound healing in angiotensin II type 1a receptor-deficient mice Biomed. Pharmacother. 63 9 2009 627 634
51. Y. Yahata, and et al. A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation J. Biol. Chem. 281 19 2006 13209 13216
52. K. Rodgers, S. Verco, L. Bolton, and G. Dizerega Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7) Expert Opin. Invest. Drugs 20 11 2011 1575 1581
53. P.P. Balingit, and et al. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial Wound Repair Regen. 20 4 2012 482 490
54. Y. Liu, and et al. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers Diabetes Care 32 1 2009 117 119
55. T. Dinh, and et al. Mechanisms involved in the development and healing of diabetic foot ulceration Diabetes 61 11 2012 2937 2947
56. R. Lobmann, and et al. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients Diabetologia 45 7 2002 1011 1016
57. E. Pirila, and et al. Collagenase-2 (MMP-8) and matrilysin-2 (MMP-26) expression in human wounds of different etiologies Wound Repair Regen. 15 1 2007 47 57
58. J.A. Uria, and C. Lopez-Otin Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity Cancer Res. 60 17 2000 4745 4751
59. R. Fridman, M. Toth, D. Pena, and S. Mobashery Activation of progelatinase B (MMP-9) by gelatinase a (MMP-2) Cancer Res. 55 12 1995 2548 2555
60. Y. Ogata, J.J. Enghild, and H. Nagase Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9 J. Biol. Chem. 267 6 1992 3581 3584
61. J. Vandooren, N. Geurts, E. Martens, P.E. Van den Steen, and G. Opdenakker Zymography methods for visualizing hydrolytic enzymes Nat. Methods 10 3 2013 211 220
62. J.Y. Hsu, and et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury J. Neurosci. 26 39 2006 9841 9850
63. D. Hesek, M. Toth, V. Krchnak, R. Fridman, and S. Mobashery Synthesis of an inhibitor-tethered resin for detection of active matrix metalloproteinases involved in disease J. Org. Chem. 71 16 2006 5848 5854
64. M. Gooyit, and et al. A chemical biological strategy to facilitate diabetic wound healing ACS Chem. Biol. 9 2014 505 510
65. S. Brown, and et al. Potent and selective mechanism-based inhibition of gelatinases J. Am. Chem. Soc. 122 28 2000 6799 6800
66. M. Lee, and et al. Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors Org. Lett. 7 20 2005 4463 4465
67. C. Forbes, and et al. Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases Chem. Biol. Drug Des. 74 6 2009 527 534
68. M. Lee, and et al. Metabolism of a highly selective gelatinase inhibitor generates active metabolite Chem. Biol. Drug Des. 70 5 2007 371 382
69. M. Gooyit, and et al. Selective water-soluble gelatinase inhibitor prodrugs J. Med. Chem. 54 19 2011 6676 6690
70. M. Gao, and et al. Acceleration of diabetic wound healing using a novel protease-anti-protease combination therapy Proc. Natl. Acad. Sci. U. S. A. 112 49 2015 15226 15231
71. S. Hernandez-Barrantes, and et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation J. Biol. Chem. 275 16 2000 12080 12089
72. M.W. Olson, D.C. Gervasi, S. Mobashery, and R. Fridman Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 J. Biol. Chem. 272 47 1997 29975 29983
73. G. Pochetti, and et al. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8) J. Med. Chem. 52 4 2009 1040 1049
74. D. Ding, K. Lichtenwalter, H. Pi, S. Mobashery, and M. Chang Characterization of a selective inhibitor for matrix metalloproteinase-8 (MMP-8) Med. Chem. Comm. 5 2014 1381 1383
75. T.R. Kyriakides, and et al. Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis Matrix Biol. 28 2 2009 65 73
76. R. Mohan, and et al. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration J. Biol. Chem. 277 3 2002 2065 2072
77. A. Ducharme, and et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction J. Clin. Invest. 106 1 2000 55 62
78. L.J. McCawley, and L.M. Matrisian Matrix metalloproteinases: they're not just for matrix anymore Curr. Opin. Cell Biol. 13 5 2001 534 540
79. B. Fingleton MMPs as therapeutic targets-still a viable option? Semin. Cell Dev. Biol. 19 1 2008 61 68